Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study)

Ronald Jahir Dominguez-Molina; Jose Pinto-Llerena

doi:doi:10.11648/j.ijcocr.20210601.13

| Peer-Reviewed

Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study)

Ronald Jahir Dominguez-Molina, Jose Pinto-Llerena

Published in International Journal of Clinical Oncology and Cancer Research (Volume 6, Issue 1)

Received: 5 January 2021 Accepted: 18 January 2021 Published: 25 January 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Sorafenib is an oral multi-kinase inhibitor that increases survival and delays tumor progression in patients with advanced hepatocarcinoma (HCC). This study aimed to determine the progression-free survival (PFS) and overall survival (OS) and to analyze OS-related factors in this population between 2014 and 2019. We performed a retrospective review of patients with advanced HCC who were treated with sorafenib at the National Cancer Institute of Panama (Instituto Oncologico Nacional de Panama – IONP) from January 2014 to December 2019. The data were collected from electronic health records of the IONP. In total, 77 patients with a mean age of 65 years were analyzed. Sixty-three percent of the patients were men, and most of them had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 and had not undergone any prior treatment. Forty-four percent patients had Child-Pugh Class A. The most frequent progression site was the liver (27%), followed by the lungs. Mean PFS was 1 month, and mean OS was 3 months. The clinical benefit was 39% and Overall response rate was 3,9%; for those with stable disease, it was 35,1%, and 3,9% showed a partial response. More encouraging results were obtained from patients with higher functional statuses (ECOG status 0-1) and who were in milder stages of liver disease (Child-Pugh Class A). The most common adverse events were fatigue, hand-foot syndrome, nausea and vomiting, and arterial hypertension. The survival results assessed in our institution for patients with advanced hepatocellular carcinoma treated with sorafenib are below of those published in the literature; however, after selecting the cases with ECOG 0-1 and Child A stage, our results were more in line with those of the international literature, being the most important prognostic factors in our patients. Fatigue and hand-foot syndrome were the most common adverse events. The key to the success of this therapy lies in an adequate selection of patients.

Published in	International Journal of Clinical Oncology and Cancer Research (Volume 6, Issue 1)
DOI	10.11648/j.ijcocr.20210601.13
Page(s)	17-21
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Hepatocarcinoma (HCC), Sorafenib, Progression-free Survival (PFS), Overall Survival (OS)

References

[1]	Ghouri Y, Mian I, Rowe J. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017; 16 (1): 1.
[2]	Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Cancer Inst. 2020; 32 (1): 5.
[3]	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394-424.
[4]	boletin_2016_rncp.pdf [Internet]. [cited 16 de enero de 2021]. Disponible in: http://minsa.b-cdn.net/sites/default/files/general/boletin_2016_rncp.pdf.
[5]	Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biol Targets Ther. 2008; 779.
[6]	Raoul J-L, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, et al. Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer. 2019; 8 (6): 457-67.
[7]	Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, et al. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol. 2018; 24 (36): 4152-63.
[8]	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008; 359 (4): 378-90.
[9]	Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, Orejana-Martín I, Torres-Jiménez J, et al. Tyrosine Kinase Receptors in Oncology. Int J Mol Sci. 2020; 21 (22): 8529.
[10]	Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol OncolJ Hematol Oncol. 2019; 12 (1): 27.
[11]	Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010; 13 (1): 1-14.
[12]	Bruix J, Raoul J-L, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol. 2012; 57 (4): 821-9.
[13]	Bruix J, Cheng A-L, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two-phase III studies. J Hepatol. 2017; 67 (5): 999-1008.
[14]	Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. Huo T-I, editor. PLOS ONE. 2016; 11 (1): e0146456.
[15]	Kurume Liver Cancer Study Group of Japan, Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, et al. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget. 2016; 7 (39): 64400-9.
[16]	Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008; 49 (2): 223-32.
[17]	Marrero JA, Kudo M, Venook AP, Ye S-L, Bronowicki J-P, Chen X-P, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol. 2016; 65 (6): 1140-7.
[18]	Shao Y-Y, Lin Z-Z, Hsu C, Shen Y-C, Hsu C-H, Cheng A-L. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010; 116 (19): 4590-6.
[19]	Brunetti O, Gnoni A, Licchetta A, Longo V, Calabrese A, Argentiero A, et al. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib [Internet]. MEDICINE & PHARMACOLOGY; 2019 sep. Disponible in: https://www.preprints.org/manuscript/201909.0071/v1.
[20]	Apostolidis L, Pfeiffenberger J, Gotthardt D, Radeleff B, Mehrabi A, Schemmer P, et al. Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. Gastrointest Tumors. 2018; 5 (1-2): 38-46.

Cite This Article

Plain Text BibTeX RIS

APA Style

Ronald Jahir Dominguez-Molina, Jose Pinto-Llerena. (2021). Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study). International Journal of Clinical Oncology and Cancer Research, 6(1), 17-21. https://doi.org/10.11648/j.ijcocr.20210601.13

Copy | Download

ACS Style

Ronald Jahir Dominguez-Molina; Jose Pinto-Llerena. Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study). Int. J. Clin. Oncol. Cancer Res. 2021, 6(1), 17-21. doi: 10.11648/j.ijcocr.20210601.13

Copy | Download

AMA Style

Ronald Jahir Dominguez-Molina, Jose Pinto-Llerena. Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study). Int J Clin Oncol Cancer Res. 2021;6(1):17-21. doi: 10.11648/j.ijcocr.20210601.13

Copy | Download

@article{10.11648/j.ijcocr.20210601.13,
  author = {Ronald Jahir Dominguez-Molina and Jose Pinto-Llerena},
  title = {Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study)},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {6},
  number = {1},
  pages = {17-21},
  doi = {10.11648/j.ijcocr.20210601.13},
  url = {https://doi.org/10.11648/j.ijcocr.20210601.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20210601.13},
  abstract = {Sorafenib is an oral multi-kinase inhibitor that increases survival and delays tumor progression in patients with advanced hepatocarcinoma (HCC). This study aimed to determine the progression-free survival (PFS) and overall survival (OS) and to analyze OS-related factors in this population between 2014 and 2019. We performed a retrospective review of patients with advanced HCC who were treated with sorafenib at the National Cancer Institute of Panama (Instituto Oncologico Nacional de Panama – IONP) from January 2014 to December 2019. The data were collected from electronic health records of the IONP. In total, 77 patients with a mean age of 65 years were analyzed. Sixty-three percent of the patients were men, and most of them had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 and had not undergone any prior treatment. Forty-four percent patients had Child-Pugh Class A. The most frequent progression site was the liver (27%), followed by the lungs. Mean PFS was 1 month, and mean OS was 3 months. The clinical benefit was 39% and Overall response rate was 3,9%; for those with stable disease, it was 35,1%, and 3,9% showed a partial response. More encouraging results were obtained from patients with higher functional statuses (ECOG status 0-1) and who were in milder stages of liver disease (Child-Pugh Class A). The most common adverse events were fatigue, hand-foot syndrome, nausea and vomiting, and arterial hypertension. The survival results assessed in our institution for patients with advanced hepatocellular carcinoma treated with sorafenib are below of those published in the literature; however, after selecting the cases with ECOG 0-1 and Child A stage, our results were more in line with those of the international literature, being the most important prognostic factors in our patients. Fatigue and hand-foot syndrome were the most common adverse events. The key to the success of this therapy lies in an adequate selection of patients.},
 year = {2021}
}

Copy | Download

TY - JOUR
T1 - Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study)
AU - Ronald Jahir Dominguez-Molina
AU - Jose Pinto-Llerena
Y1 - 2021/01/25
PY - 2021
N1 - https://doi.org/10.11648/j.ijcocr.20210601.13
DO - 10.11648/j.ijcocr.20210601.13
T2 - International Journal of Clinical Oncology and Cancer Research
JF - International Journal of Clinical Oncology and Cancer Research
JO - International Journal of Clinical Oncology and Cancer Research
SP - 17
EP - 21
PB - Science Publishing Group
SN - 2578-9511
UR - https://doi.org/10.11648/j.ijcocr.20210601.13
AB - Sorafenib is an oral multi-kinase inhibitor that increases survival and delays tumor progression in patients with advanced hepatocarcinoma (HCC). This study aimed to determine the progression-free survival (PFS) and overall survival (OS) and to analyze OS-related factors in this population between 2014 and 2019. We performed a retrospective review of patients with advanced HCC who were treated with sorafenib at the National Cancer Institute of Panama (Instituto Oncologico Nacional de Panama – IONP) from January 2014 to December 2019. The data were collected from electronic health records of the IONP. In total, 77 patients with a mean age of 65 years were analyzed. Sixty-three percent of the patients were men, and most of them had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 and had not undergone any prior treatment. Forty-four percent patients had Child-Pugh Class A. The most frequent progression site was the liver (27%), followed by the lungs. Mean PFS was 1 month, and mean OS was 3 months. The clinical benefit was 39% and Overall response rate was 3,9%; for those with stable disease, it was 35,1%, and 3,9% showed a partial response. More encouraging results were obtained from patients with higher functional statuses (ECOG status 0-1) and who were in milder stages of liver disease (Child-Pugh Class A). The most common adverse events were fatigue, hand-foot syndrome, nausea and vomiting, and arterial hypertension. The survival results assessed in our institution for patients with advanced hepatocellular carcinoma treated with sorafenib are below of those published in the literature; however, after selecting the cases with ECOG 0-1 and Child A stage, our results were more in line with those of the international literature, being the most important prognostic factors in our patients. Fatigue and hand-foot syndrome were the most common adverse events. The key to the success of this therapy lies in an adequate selection of patients.
VL - 6
IS - 1
ER -

Copy | Download

Author Information

Ronald Jahir Dominguez-Molina

Medical Oncology Fellow, Department of Medical Oncology, National Cancer Institute, Panama City, Panama
Jose Pinto-Llerena

Medical Oncology, Unit of Gastrointestinal Tumors, Department of Medical Oncology, National Cancer Institute, Panama City, Panama

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Ronald Jahir Dominguez-Molina, Jose Pinto-Llerena. (2021). Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study). International Journal of Clinical Oncology and Cancer Research, 6(1), 17-21. https://doi.org/10.11648/j.ijcocr.20210601.13

Copy | Download

ACS Style

Ronald Jahir Dominguez-Molina; Jose Pinto-Llerena. Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study). Int. J. Clin. Oncol. Cancer Res. 2021, 6(1), 17-21. doi: 10.11648/j.ijcocr.20210601.13

Copy | Download

AMA Style

Ronald Jahir Dominguez-Molina, Jose Pinto-Llerena. Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study). Int J Clin Oncol Cancer Res. 2021;6(1):17-21. doi: 10.11648/j.ijcocr.20210601.13

Copy | Download

@article{10.11648/j.ijcocr.20210601.13,
  author = {Ronald Jahir Dominguez-Molina and Jose Pinto-Llerena},
  title = {Experience with Sorafenib in Patients with Advanced Hepatocellular Carcinoma Treated at the National Cancer Institute of Panama (Sorafen Study)},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {6},
  number = {1},
  pages = {17-21},
  doi = {10.11648/j.ijcocr.20210601.13},
  url = {https://doi.org/10.11648/j.ijcocr.20210601.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20210601.13},
  abstract = {Sorafenib is an oral multi-kinase inhibitor that increases survival and delays tumor progression in patients with advanced hepatocarcinoma (HCC). This study aimed to determine the progression-free survival (PFS) and overall survival (OS) and to analyze OS-related factors in this population between 2014 and 2019. We performed a retrospective review of patients with advanced HCC who were treated with sorafenib at the National Cancer Institute of Panama (Instituto Oncologico Nacional de Panama – IONP) from January 2014 to December 2019. The data were collected from electronic health records of the IONP. In total, 77 patients with a mean age of 65 years were analyzed. Sixty-three percent of the patients were men, and most of them had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 and had not undergone any prior treatment. Forty-four percent patients had Child-Pugh Class A. The most frequent progression site was the liver (27%), followed by the lungs. Mean PFS was 1 month, and mean OS was 3 months. The clinical benefit was 39% and Overall response rate was 3,9%; for those with stable disease, it was 35,1%, and 3,9% showed a partial response. More encouraging results were obtained from patients with higher functional statuses (ECOG status 0-1) and who were in milder stages of liver disease (Child-Pugh Class A). The most common adverse events were fatigue, hand-foot syndrome, nausea and vomiting, and arterial hypertension. The survival results assessed in our institution for patients with advanced hepatocellular carcinoma treated with sorafenib are below of those published in the literature; however, after selecting the cases with ECOG 0-1 and Child A stage, our results were more in line with those of the international literature, being the most important prognostic factors in our patients. Fatigue and hand-foot syndrome were the most common adverse events. The key to the success of this therapy lies in an adequate selection of patients.},
 year = {2021}
}

Copy | Download